Tumor mimicking actinomycosis of the upper lip: report of two cases

Kuyama, Kayo; Sun, Yan; Fukui, Kenji; Maruyama, Satoshi; Ochiai, Eriko; Fukumoto, Masahiko; Ikeda, Nobuyuki; Kondoh, T.; Iwadate, Kimiharu; Takagi, Ritsuo; Saku, Takashi; Yamamoto, Hirotsugu

doi:10.3353/omp.15.95

Cited by 4 publications

(2 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…israelii is the main causative bacteria 13 . In the intraoral mucosal region, actinomycosis is rarely seen,14, 15 and causative organisms that enter tissues through an area are sometimes prior triggers. We considered hypotheses about the generating mechanism in this case.…”

Section: Discussionmentioning

confidence: 99%

Pyogenic granuloma associated with Actinomyces israelii

Kuyama

Fukui

Ochiai

et al. 2018

Journal of Dental Sciences

Self Cite

View full text Add to dashboard Cite

Peculiar findings of orofacial actinomycosis mimicking the clinical appearance of a tumor of the upper gingiva are reported. An 83-year-old man with bleeding of the gingiva visited our hospital. The clinical diagnosis was a benign gingival tumor, and the lesion was surgically removed. Histologically, the excised specimens showed an ulcerative granuloma lesion covered by bacterial colonies consisting of club-shaped filaments. DNA samples were extracted from paraffin sections and examined by polymerase chain reaction (PCR) for Actinomyces species. The PCR products examined by direct DNA sequencing demonstrated the presence of Actinomyces israelii . Finally, a pathological diagnosis was made of a pyogenic granuloma associated with actinomycosis. The PCR method aided the early and exact diagnosis of the paraffin-embedded sample of oral mucosal infectious diseases including actinomycosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Pyogenic granuloma associated with Actinomyces israelii

Kuyama

Fukui

Ochiai

et al. 2018

Journal of Dental Sciences

Self Cite

View full text Add to dashboard Cite

show abstract

“…By contrast, the tissue samples for histological examination do not require any special treatment and the diagnosis of actinomycosis relies only on the detection of sulfur granules ( 48 ). Therefore, the final diagnosis has a tendency to depend on histopathological confirmation ( 51 ). This explains the discrepancy in the results of the case reported in the current study.…”

Section: Discussionmentioning

confidence: 99%

Denosumab-related osteonecrosis of the jaw in a patient with bone metastases of prostate cancer: A case report and literature review

et al. 2017

View full text Add to dashboard Cite

Denosumab, a human monoclonal antibody directed against the receptor activator of nuclear factor-κβ ligand (RANKL), is used for the treatment of patients with metastatic cancer of the bone or osteoporosis. Recent reports have demonstrated that denosumab can induce osteonecrosis of the jaw (ONJ), but reported cases of this are uncommon. The present study reports the case of an 86-year-old male with prostate cancer patient exhibiting bone metastases who developed ONJ whilst receiving denosumab. To elucidate the influence of denosumab on the development of ONJ, the present study also reviewed the literature, including clinical trials and case reports. In the clinical trials, the prevalence of denosumab-related ONJ was higher in patients with cancer compared with those with osteoporosis. The high risk of ONJ in patients with cancer was thought to be associated with the differing dose and frequency of denosumab administration. The prevalence of ONJ was not significantly different between patients receiving denosumab and bisphoshonate (BP). In the reported cases, denosumab-related ONJ had a similar clinical presentation to BP-related ONJ. There was also a tendency for denosumab-related ONJ to develop in the mandible of elderly patients. Previous invasive dental treatment was a commonly shared characteristic of patients with denosumab-related ONJ. A complex medical history was also suspected to affect the prevalence. No clear association between the dose or duration of denosumab treatment and the development of ONJ was observed. Although conservative treatments are given for denosumab-related ONJ, non-improving cases were managed surgically with primarily positive results. Because denosumab may offer superior results compared with BP for the treatment of metastatic cancer of the bone or osteoporosis, the use of denosumab is expected to increase in the near future. Clinicians should also be aware of the risk factors for denosumab-related ONJ, in order to aid in its diagnosis. In addition, patients treated with denosumab should receive prophylactic treatment to maintain their oral health prior to, during and after denosumab treatment.

show abstract